By Professor David Thomas

Book Chapters

Neuhaus SJ; Thomas DM, 2017, 'Multidisciplinary approach to treatment: An Australian perspective', in Sarcoma: A Multidisciplinary Approach to Treatment, Springer, pp. 461 - 476, http://dx.doi.org/10.1007/978-3-319-43121-5_23

Thomas DM; Whelan J, 2017, 'Bone Sarcomas in the Adolescent and Young Adult Population', in Bleyer A; Barr R; Ries L; Whelan J; Ferrari A (ed.), Cancer in Adolescents and Young Adults., Springer, pp. 417 - 427, http://dx.doi.org/10.1007/978-3-319-33679-4_16

Orme LM; Palmer S; Thomas D, 2009, 'No-man’s land: Between paediatric and adult medical oncology', in When Cancer Crosses Disciplines A Physician S Handbook, pp. 885 - 906, http://dx.doi.org/10.1142/9781848163652_0035

Journal articles

Cai Z; Boys EL; Noor Z; Aref AT; Xavier D; Lucas N; Williams SG; Koh JM; Poulos RC; Wu Y; Dausmann M; MacKenzie KL; Aguilar-Mahecha A; Armengol C; Barranco MM; Basik M; Bowman ED; Clifton-Bligh R; Connolly EA; Cooper WA; Dalal B; DeFazio A; Filipits M; Flynn PJ; Graham JD; George J; Gill AJ; Gnant M; Habib R; Harris CC; Harvey K; Horvath LG; Jackson C; Kohonen-Corish MRJ; Lim E; Liu JJ; Long GV; Lord RV; Mann GJ; McCaughan GW; Morgan L; Murphy L; Nagabushan S; Nagrial A; Navinés J; Panizza BJ; Samra JS; Scolyer RA; Souglakos J; Swarbrick A; Thomas D; Balleine RL; Hains PG; Robinson PJ; Zhong Q; Reddel RR, 2025, 'Federated deep learning enables cancer subtyping by proteomics.', Cancer Discov, http://dx.doi.org/10.1158/2159-8290.CD-24-1488

Connolly EA; Boye K; Bonvalot S; Kratz CP; Leithner A; Malkin D; Messiou C; Miah AB; Pantziarka P; Timmermann B; van der Graaf WTA; Thomas DM; Stacchiotti S, 2025, 'Genetic predisposition in sarcomas: clinical implications and management', Eclinicalmedicine, 83, http://dx.doi.org/10.1016/j.eclinm.2025.103203

Gadgeel SM; Fajardo O; Barlesi F; Eun Kim J; Kurzrock R; Thomas DM; Jagtiani R; Noe J; Schwemmers S; Nikolaidis C, 2025, 'Real-world characteristics and survival outcomes of patients with metastatic ALK fusion-positive solid tumors treated with standard-of-care therapies', Oncologist, 30, http://dx.doi.org/10.1093/oncolo/oyaf005

McParland K; Koh ES; Kong B; Sim HW; Thavaneswaran S; Yip S; Barnes EH; Ballinger ML; Thomas DM; De Abreu Lourenco R; Simes J; Sebastian L; Wheeler PJ; Spyridopoulos D; Hawkins C; Pitz M; O'Callaghan C; Gan HK, 2025, 'Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2): study protocol for a phase 2, prospective, multicentre, open-label, multiarm, biomarker-directed, signal-seeking, umbrella, clinical trial for recurrent IDH mutant, grade 2/3 glioma', BMJ Open, 15, pp. e087922, http://dx.doi.org/10.1136/bmjopen-2024-087922

Novis E; Glover A; Grady JP; Silvestri A; Thavaneswaran S; Lin F; Ballinger ML; Thomas DM, 2025, 'Oncogenic mutations in the TP53 and PI-3 kinase/AKT pathway are independent predictors of survival for advanced thyroid cancer: Analysis from the Molecular Screening and Therapeutics (MoST) program', Surgery United States, 177, http://dx.doi.org/10.1016/j.surg.2024.05.058

Ballinger ML; Thomas DM, 2025, 'POT1 clinical risk management is an open question', European Journal of Human Genetics, 33, pp. 3 - 4, http://dx.doi.org/10.1038/s41431-024-01676-x

Horgan D; Tanner M; Aggarwal C; Thomas D; Grover S; Basel-Salmon L; Dienstmann R; Tan TJY; Park WY; Abu Rasheed HM; Siu LL; Ma B; Ortiz-López R; Van Den Bulcke M; Taucher SC; Ferris A; Starling N; Malapelle U; Longshore J; Saldaña HAB; Subbiah V, 2025, 'Precision Oncology: A Global Perspective on Implementation and Policy Development', JCO Global Oncology, 11, http://dx.doi.org/10.1200/GO-24-00416

Zhu Y; Lin FP-Y; So JY; Oh EW; Philipsen S; Thomas DM; Grady JP; Lawrence BJ; Wilson MK, 2025, 'Actionability of genomic alterations in the Molecular Screening and Therapeutics (MoST) program in New Zealand (NZ) depending on residence in NZ or Australia.', Journal of Clinical Oncology, 43, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.e13763

Spencer S; Ye W; Napier C; Lin FP-Y; Thomas DM; Chan R; Ballinger ML; Morton RL; Berber S; Zou D; Peng S, 2025, 'Clinical and economic value of comprehensive genomic profiling in patients with advanced solid cancers using Australian real-world data: Preliminary analyses.', Journal of Clinical Oncology, 43, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.e15084

Lin FP-Y; Goldstein D; Grady JP; Napier C; Thavaneswaran S; Pitiyarachchi O; Kansara M; Chantrill LA; Sjoquist K; Thornton K; Raina A; Magenau A; Simes J; Ballinger ML; Sharbeen G; Timpson P; Pajic M; Phillips P; Thomas DM, 2025, 'Genomic and outcome analysis of recurrent versus de novo metastatic pancreatic ductal adenocarcinoma (PDAC) receiving systemic therapy: Results from the Australian MoST and CaSP screening programs.', Journal of Clinical Oncology, 43, pp. 4120 - 4120, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.4120

Lin FP-Y; Huang ML; Grady JP; Thavaneswaran S; Kansara M; Napier C; Ballinger ML; Simes J; Thomas DM, 2025, 'Machine learning–based classification of cancer types using genomic profiling data from the Australian Molecular Screening and Therapeutics (MoST) program.', Journal of Clinical Oncology, 43, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.e13683

Kohlmann W; Curtin K; Madsen MJ; Camp NJ; Jeter JM; Ballinger ML; Thomas DM; Garber JE; Schiffman JD, 2025, 'Population-based assessment of leiomyosarcoma (LMS) and cancers in the Li-Fraumeni syndrome (LFS) spectrum: Implications for genetic testing criteria.', Journal of Clinical Oncology, 43, pp. 11570 - 11570, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.11570

Thavaneswaran S; Sim H-W; Grady J; Espinoza D; Huang ML; Lin F; Mcgrath M; Desai J; Charakidis M; Brown M; Kansara M; Simes J; Thomas D, 2024, 'A phase II trial of larotrectinib in tumors with NTRK fusions or extremes of NTRK mRNA overexpression identified by comprehensive genomic profiling', ONCOLOGIST, http://dx.doi.org/10.1093/oncolo/oyae339

Thavaneswaran S; Lin F; Grady JP; Espinoza D; Huang ML; Chinchen S; Sebastian L; Kansara M; Mersiades T; Lee CK; Desai J; Grimison P; Brown M; Millward M; Harrup R; O’Byrne K; Nagrial A; Craft P; Simes J; Joshua AM; Thomas DM, 2024, 'A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation', Npj Precision Oncology, 8, http://dx.doi.org/10.1038/s41698-024-00698-4

Collet L; Telouk P; Albarede F; Girodet M; Maqua C; Rogasik M; Ducimetière F; Tabone-Eglinger S; Brahmi M; Dufresne A; Thomas DM; Ballinger ML; Blay JY; Ray-Coquard I, 2024, 'Connecting the changing trace elements spectrum and survival in sarcoma: a pilot study', Metabolomics, 20, http://dx.doi.org/10.1007/s11306-024-02178-z

Takeda K; Nakayama M; Hayakawa Y; Kojima Y; Ikeda H; Imai N; Ogasawara K; Okumura K; Thomas DM; Smyth MJ, 2024, 'Correction to: IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting (Nature Communications, (2017), 8, 1, (14607), 10.1038/ncomms14607)', Nature Communications, 15, http://dx.doi.org/10.1038/s41467-024-53456-2

Deng F; Li Y; Yang B; Sang R; Deng W; Kansara M; Lin F; Thavaneswaran S; Thomas DM; Goldys EM, 2024, 'Topological barrier to Cas12a activation by circular DNA nanostructures facilitates autocatalysis and transforms DNA/RNA sensing', Nature Communications, 15, pp. 1818, http://dx.doi.org/10.1038/s41467-024-46001-8

Gianferante DM; Moore A; Spector LG; Wheeler W; Yang T; Hubbard A; Gorlick R; Patiño-Garcia A; Lecanda F; Flanagan AM; Amary F; Andrulis IL; Wunder JS; Thomas DM; Ballinger ML; Serra M; Hattinger C; Demerath E; Johnson W; Birmann BM; De Vivo I; Giles G; Teras LR; Arslan A; Vermeulen R; Sample J; Freedman ND; Huang WY; Chanock SJ; Savage SA; Berndt SI; Mirabello L, 2024, 'Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma', Cancer Epidemiology, 92, http://dx.doi.org/10.1016/j.canep.2023.102432

Best MC; Butow P; Savard J; Newson AJ; Campbell R; Vatter S; Napier CE; Bartley N; Tucker K; Ballinger ML; Thomas DM; Juraskova I; Schlub T; Davies G; Meiser B; Goldstein D, 2024, 'From ownership to custodianship of tumor biopsy tissue in genomic testing: A mixed methods study of patient views', Oncologist, 29, pp. e1169 - e1179, http://dx.doi.org/10.1093/oncolo/oyae074

Barjesteh van Waalwijk van Doorn-Khosrovani S; Kholmanskikh Van Criekingen O; Koole S; Thomas DM; Gelderblom H, 2024, 'Testing dilemmas in the clinic: Lessons learned from biomarker-based drug development', Cancer Cell, 42, pp. 923 - 929, http://dx.doi.org/10.1016/j.ccell.2024.05.014

Freeman B; Peters MJ; Bittoun R; Brightwell R; English DR; Thomas DP; Otlowski MFA; Zwar NA; Chamberlain C, 2024, 'National Health and Medical Research Council statement on electronic cigarettes: 2022 update', Medical Journal of Australia, 220, pp. 100 - 106, http://dx.doi.org/10.5694/mja2.52163

Ringborg U; von Braun J; Celis J; Baumann M; Berns A; Eggermont A; Heard E; Heitor M; Chandy M; Chen CJ; Costa A; De Lorenzo F; De Robertis EM; Dubee FC; Ernberg I; Gabriel M; Helland Å; Henrique R; Jönsson B; Kallioniemi O; Korbel J; Krause M; Lowy DR; Michielin O; Nagy P; Oberst S; Paglia V; Parker MI; Ryan K; Sawyers CL; Schüz J; Silkaitis K; Solary E; Thomas D; Turkson P; Weiderpass E; Yang H, 2024, 'Strategies to decrease inequalities in cancer therapeutics, care and prevention: Proceedings on a conference organized by the Pontifical Academy of Sciences and the European Academy of Cancer Sciences, Vatican City, February 23–24, 2023', Molecular Oncology, 18, pp. 245 - 279, http://dx.doi.org/10.1002/1878-0261.13575

Mersiades AJ; Solomon Benjamin J; Thomas David M; Lee CK; Cummins MM; Sebastian L; Ballinger ML; Collignon E; Turnbull OMH; Yip S; Morton RL; Brown C; Wheeler PJ; Itchins M; Simes RJ; Pavlakis N, 2024, 'ASPiRATION: Australian Observational Cohort Study of Comprehensive Genomic Profiling in Metastatic Lung Cancer Tissue', Future Oncology, 20, pp. 361 - 371, http://dx.doi.org/10.2217/fon-2023-0366

Fortuno C; Feng BJ; Carroll C; Innella G; Kohlmann W; Lázaro C; Brunet J; Feliubadaló L; Iglesias S; Menéndez M; Teulé A; Ballinger ML; Thomas DM; Campbell A; Field M; Harris M; Kirk J; Pachter N; Poplawski N; Susman R; Tucker K; Wallis M; Williams R; Cops E; Goldgar D; Investigators KCF; James PA; Spurdle AB, 2024, 'Cancer Risks Associated With TP53 Pathogenic Variants: Maximum Likelihood Analysis of Extended Pedigrees for Diagnosis of First Cancers Beyond the Li-Fraumeni Syndrome Spectrum', JCO Precision Oncology, 8, http://dx.doi.org/10.1200/PO.23.00453

Cho D; Lord SJ; Ward R; IJzerman M; Mitchell A; Thomas DM; Cheyne S; Martin A; Morton RL; Simes J; Lee CK, 2024, 'Criteria for assessing evidence for biomarker-targeted therapies in rare cancers—an extrapolation framework', Therapeutic Advances in Medical Oncology, 16, http://dx.doi.org/10.1177/17588359241273062

Sargen MR; Kim J; Haley JS; Barker HP; Mundra PA; Ballinger ML; Thomas DM; Carey DJ; Goldstein AM; Stewart DR, 2024, 'Increased frequency of CHEK2 germline pathogenic variants among individuals with dermatofibrosarcoma protuberans', Genetics in Medicine Open, 2, http://dx.doi.org/10.1016/j.gimo.2024.101895

Walpole IR; Zaman FY; Zhao P; Marshall VM; Lin FP; Thomas DM; Shackleton M; Antolin AA; Ameratunga M, 2024, 'Computational repurposing of oncology drugs through off-target drug binding interactions from pharmacological databases', CLINICAL AND TRANSLATIONAL MEDICINE, 14, http://dx.doi.org/10.1002/ctm2.1657

Sharaf R; Jin DX; Grady J; Napier C; Ebot E; Frampton GM; Albacker LA; Thomas DM; Montesion M, 2023, 'A pan-sarcoma landscape of telomeric content shows that alterations in RAD51B and GID4 are associated with higher telomeric content', Npj Genomic Medicine, 8, http://dx.doi.org/10.1038/s41525-023-00369-6

Lu CY; Terry V; Thomas DM, 2023, 'Precision medicine: affording the successes of science', Npj Precision Oncology, 7, http://dx.doi.org/10.1038/s41698-022-00343-y

Vaghjiani VG; Cochrane CR; Jayasekara WSN; Chong WC; Szczepny A; Kumar B; Martelotto LG; McCaw A; Carey K; Kansara M; Thomas DM; Walkley C; Mudge S; Gough DJ; Downie PA; Peacock CD; Matsui W; Watkins DN; Cain JE, 2023, 'Ligand-dependent hedgehog signaling maintains an undifferentiated, malignant osteosarcoma phenotype', Oncogene, 42, pp. 3529 - 3541, http://dx.doi.org/10.1038/s41388-023-02864-7

McNamee N; Lin F; Sim H-W; Napier C; Thomas D; Simes J; Thavaneswaran S, 2023, 'PATH-25. EXPLORING THE PROGNOSTIC IMPLICATIONS OF MOLECULAR ALTERATIONS IN ASTROCYTOMAS USING COMPREHENSIVE GENOMIC PROFILING (CGP)', Neuro-Oncology, 25, pp. v173 - v173, http://dx.doi.org/10.1093/neuonc/noad179.0655

Le Tourneau C; André F; Helland Å; Mileshkin L; Minnaard W; Schiel A; Taskén K; Thomas DM; Veronese ML; Durán-Pacheco G; Leyens L; Rufibach K; Thomas M; Krämer A, 2023, 'Modified study designs to expand treatment options in personalised oncology: a multistakeholder view', European Journal of Cancer, 194, http://dx.doi.org/10.1016/j.ejca.2023.113278

Ng JY; Warwick L; Craft P; Austen L; Ashford B; Gorddard N; Ballinger ML; Thomas DM; Blombery P; Tucker K; Polizzotto MN, 2023, 'Myelodysplastic syndrome and multiple solid tumours in an individual with compound heterozygous deleterious FANCM variants: A case report and review of the literature', British Journal of Haematology, 203, pp. 481 - 484, http://dx.doi.org/10.1111/bjh.19059

Zeverijn LJ; Looze EJ; Thavaneswaran S; van Berge Henegouwen JM; Simes RJ; Hoes LR; Sjoquist KM; van der Wijngaart H; Sebastian L; Geurts BS; Lee CK; de Wit GF; Espinoza D; Roepman P; Lin FP; Jansen AML; de Leng WWJ; van der Noort V; Leek LVM; de Vos FYFL; van Herpen CML; Gelderblom H; Verheul HMW; Thomas DM; Voest EE, 2023, 'Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials', International Journal of Cancer, 153, pp. 1413 - 1422, http://dx.doi.org/10.1002/ijc.34649

Harrison C; Bartley N; Jacobs C; Best M; Vatter S; Meiser B; Ballinger ML; Thomas DM; Butow P, 2023, 'Family communication and results disclosure after germline sequencing: A mixed methods study', Patient Education and Counseling, 114, http://dx.doi.org/10.1016/j.pec.2023.107800

Sabesan S; Malica M; Gebbie C; Scott C; Thomas D; Zalcberg J, 2023, 'Implementation of the Australasian Teletrial Model: Translating ideas into action using implementation science frameworks', Journal of Telemedicine and Telecare, 29, pp. 641 - 647, http://dx.doi.org/10.1177/1357633X211017805

Thavaneswaran S; Kansara M; Lin F; Espinoza D; Grady JP; Lee CK; Ballinger ML; Sebastian L; Corpuz T; Qiu MR; Mundra P; Bailey CG; Schmitz U; Simes J; Joshua AM; Thomas DM, 2023, 'A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations', British Journal of Cancer, 129, pp. 475 - 485, http://dx.doi.org/10.1038/s41416-023-02311-0

Zeverijn LJ; Looze E; Thavaneswaran S; van Berge Henegouwen JM; Simes J; Hoes LR; Geurts B; Sebastian L; Roepman P; Lin FP-Y; Jansen AML; de Leng WWJ; van der Noort V; Leek LVM; De Vos FYFL; Verheul HMW; Gelderblom H; Thomas DM; Voest EE; Sjoquist KM, 2023, 'Clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.', Journal of Clinical Oncology, 41, pp. 3101 - 3101, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3101

Kansara M; Lin FP-Y; Thavaneswaran S; Napier CE; Grady JP; Ballinger ML; Simes J; Thomas DM, 2023, 'Genomic alterations associated with response to immune checkpoint inhibitors in rare cancers: A biomarker exploration study from the Australian Molecular Screening and Therapeutics (MoST) Program.', Journal of Clinical Oncology, 41, pp. 2594 - 2594, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.2594

Thavaneswaran S; Lin FP-Y; Napier CE; Grady JP; Ballinger ML; Kansara M; Grimison PS; Pavlakis N; Wong MK; Sjoquist KM; Goldstein D; Chantrill LA; Simes J; Thomas DM, 2023, 'Genomic targetability and survival outcomes of biliary tract cancers (BTC): A retrospective cohort study of the Australian Molecular Screening and Therapeutics (MoST) program.', Journal of Clinical Oncology, 41, pp. 4093 - 4093, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.4093

Lin FP-Y; Thavaneswaran S; Napier CE; Grady JP; Kansara M; Sebastian L; Kee D; Zaheed M; Millward M; Brown MP; Charakidis M; Craft PS; Grimison PS; Harrup RA; O'Byrne KJ; Desai J; Lee CK; Ballinger ML; Simes J; Thomas DM, 2023, 'Genomic therapy matching in rare and refractory cancers: Updated results from a retrospective cohort study in the Molecular Screening and Therapeutic (MoST) program.', Journal of Clinical Oncology, 41, pp. 1540 - 1540, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.1540

Zaheed M; Napier CE; Cops EJ; Ferris N; Moodie K; Milner B; Moses D; Poplawski N; Dow EG; Harris M; Tucker K; Trainer A; James P; Thomas DM; Ballinger ML, 2023, 'Long-term clinical and psychosocial outcomes of surveillance in Li Fraumeni syndrome.', Journal of Clinical Oncology, 41, pp. 10578 - 10578, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.10578

Kee D; Lin FP-Y; Thavaneswaran S; Napier CE; Harrison ML; Beale PJ; Lynch J; Davis AJ; Ananda S; Lombard JM; Friedlander M; Kansara M; Sebastian L; Lee CK; Ballinger ML; Simes J; Thomas DM, 2023, 'Molecular tumor profiling and therapy selection in advanced gynecological cancers: A retrospective cohort analysis from the Australian Molecular Screening and Therapeutics (MoST) Program.', Journal of Clinical Oncology, 41, pp. 5526 - 5526, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5526

Thavaneswaran S; Mersiades A; Lin FP-Y; Espinoza D; Grady JP; Lee CK; Desai J; Brown MP; Grimison PS; O'Byrne KJ; Harrup RA; Nagrial A; Sebastian L; Chinchen S; Kansara M; Craft PS; Millward M; Simes J; Joshua AM; Thomas DM, 2023, 'Trastuzumab emtansine (T-DM1) in advanced cancers with HER2 mutations or amplification: Results from the Molecular Screening and Therapeutics (MoST) Program substudy.', Journal of Clinical Oncology, 41, pp. 3127 - 3127, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3127

Stark Z; Boughtwood T; Haas M; Braithwaite J; Gaff CL; Goranitis I; Spurdle AB; Hansen DP; Hofmann O; Laing N; Metcalfe S; Newson AJ; Scott HS; Thorne N; Ward RL; Dinger ME; Best S; Long JC; Grimmond SM; Pearson J; Waddell N; Barnett CP; Cook M; Field M; Fielding D; Fox SB; Gecz J; Jaffe A; Leventer RJ; Lockhart PJ; Lunke S; Mallett AJ; McGaughran J; Mileshkin L; Nones K; Roscioli T; Scheffer IE; Semsarian C; Simons C; Thomas DM; Thorburn DR; Tothill R; White D; Dunwoodie S; Simpson PT; Phillips P; Brion MJ; Finlay K; Quinn MC; Mattiske T; Tudini E; Boggs K; Murray S; Wells K; Cannings J; Sinclair AH; Christodoulou J; North KN, 2023, 'Australian Genomics: Outcomes of a 5-year national program to accelerate the integration of genomics in healthcare', American Journal of Human Genetics, 110, pp. 419 - 426, http://dx.doi.org/10.1016/j.ajhg.2023.01.018

Kansara M; Bhardwaj N; Thavaneswaran S; Xu C; Lee JK; Chang LB; Madison RW; Lin F; Hsu E; Patel VK; Aleshin A; Oxnard GR; Simes J; Nimeiri H; Thomas DM, 2023, 'Early circulating tumor DNA dynamics as a pan-tumor biomarker for long-term clinical outcome in patients treated with durvalumab and tremelimumab', Molecular Oncology, 17, pp. 298 - 311, http://dx.doi.org/10.1002/1878-0261.13349

Ballinger ML; Pattnaik S; Mundra PA; Zaheed M; Rath E; Priestley P; Baber J; Ray-Coquard I; Isambert N; Causeret S; van der Graaf WTA; Puri A; Duffaud F; Le Cesne A; Seddon B; Chandrasekar C; Schiffman JD; Brohl AS; James PA; Kurtz JE; Penel N; Myklebost O; Meza-Zepeda LA; Pickett H; Kansara M; Waddell N; Kondrashova O; Pearson JV; Barbour AP; Li S; Nguyen TL; Fatkin D; Graham RM; Giannoulatou E; Green MJ; Kaplan W; Ravishankar S; Copty J; Powell JE; Cuppen E; van Eijk K; Veldink J; Ahn JH; Kim JE; Lor Randall R; Tucker K; Judson I; Sarin R; Ludwig T; Genin E; Deleuze JF; Haber M; Marshall G; Cairns MJ; Blay JY; Thomas DM, 2023, 'Heritable defects in telomere and mitotic function selectively predispose to sarcomas', Science, 379, pp. 253 - 260, http://dx.doi.org/10.1126/science.abj4784

Back to profile page